It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The disruption in blood supply due to myocardial infarction is a critical determinant for infarct size and subsequent deterioration in function. The identification of factors that enhance cardiac repair by the restoration of the vascular network is, therefore, of great significance. Here, we show that the transcription factor Zinc finger E-box-binding homeobox 2 (ZEB2) is increased in stressed cardiomyocytes and induces a cardioprotective cross-talk between cardiomyocytes and endothelial cells to enhance angiogenesis after ischemia. Single-cell sequencing indicates ZEB2 to be enriched in injured cardiomyocytes. Cardiomyocyte-specific deletion of ZEB2 results in impaired cardiac contractility and infarct healing post-myocardial infarction (post-MI), while cardiomyocyte-specific ZEB2 overexpression improves cardiomyocyte survival and cardiac function. We identified Thymosin β4 (TMSB4) and Prothymosin α (PTMA) as main paracrine factors released from cardiomyocytes to stimulate angiogenesis by enhancing endothelial cell migration, and whose regulation is validated in our in vivo models. Therapeutic delivery of ZEB2 to cardiomyocytes in the infarcted heart induces the expression of TMSB4 and PTMA, which enhances angiogenesis and prevents cardiac dysfunction. These findings reveal ZEB2 as a beneficial factor during ischemic injury, which may hold promise for the identification of new therapies.
ZEB2 transcription factor is increased in a subset of cardiomyocytes during stress to induce cardioprotective effects after injury. Here the authors show that therapeutic delivery of ZEB2 prevents cardiac dysfunction after ischemic damage and promotes the activation of pro-angiogenic signals.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Centre, Hubrecht Institute, Utrecht, The Netherlands (GRID:grid.418101.d) (ISNI:0000 0001 2153 6865)
2 Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Centre, Hubrecht Institute, Utrecht, The Netherlands (GRID:grid.418101.d) (ISNI:0000 0001 2153 6865); University Medical Center, Department of Cardiology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
3 Amsterdam University Medical Center VU, Department of Physiology, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262); Amsterdam University Medical Center, Department of Medical Biochemistry, Amsterdam, The Netherlands (GRID:grid.7177.6)
4 University Medical Center, Molecular Cancer Research, Center for Molecular Medicine, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
5 University Medical Centre Utrecht, Department of Pathology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
6 University of Manitoba, Department of Pharmacology and Therapeutics, Winnipeg, Canada (GRID:grid.21613.37) (ISNI:0000 0004 1936 9609)
7 Erasmus University Medical Centre, Department of Cell Biology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); University of Leuven, Department of Development and Regeneration, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
8 Amsterdam University Medical Center VU, Department of Physiology, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262); Goethe University, Institute for Cardiovascular Regeneration, Centre for Molecular Medicine, Frankfurt am Main, Germany (GRID:grid.7839.5) (ISNI:0000 0004 1936 9721); German Center for Cardiovascular Research (DZHK), Frankfurt am Main, Germany (GRID:grid.452396.f) (ISNI:0000 0004 5937 5237)
9 School of Cardiovascular Medicine and Sciences, King’s College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)